Loading clinical trials...
Loading clinical trials...
The purpose of this study is to evaluate the long-term safety and efficacy of OraVescent fentanyl to treat breakthrough pain episodes in cancer patients who are already opioid tolerant.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Cephalon
NCT07231419 · Diabetic Peripheral Neuropathic Pain
NCT04541381 · Gastrointestinal Cancer, Head and Neck Cancer, and more
NCT07553000 · Wrist Injuries, Wrist Fracture, and more
NCT06382272 · Mastectomy, Breast, and more
NCT05468034 · Breast Cancer, Indolent Metastatic Breast Cancer
Center for Pain Management
Huntsville, Alabama
Outcomes Research International
Tucson, Arizona
Arizona Clinical Research Center
Tucson, Arizona
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions